HOME
.JPG)
Our Mission:
IRAD Oncology is developing novel cancer drugs that have better efficacy and lower side effects than existing cancer chemotherapy drugs.
Drugs:
Our lead drug, IRAD-MTX is a conjugate of the effective chemotherapy drug methotrexate to a targeting protein. IRAD-MTX was 15-times more effective than methotrexate in animal studies, and with much lower side effects. It has completed a Phase 1 study in advanced solid tumors and was effective even as a single agent in persons with heavily pre-treated advanced tumors that had progressed on approved drugs. And it had extremely low side effects, with no decrease in blood cell counts, unlike methotrexate and all chemotherapy drugs.
https://clinicaltrials.gov/ct2/show/NCT02045368. https://www.ncbi.nlm.nih.gov/pubmed/31633515IRAD-MTX is now in a second clinical trial at the Mayo Clinic in the blood cancer myelodysplastic syndrome (MDS). Early results again show very promising efficacy
and low side effects.
We also have a further pipeline of targeted cancer drugs.
About Us:
IRAD Oncology INC. is committed to advancing bladder cancer research and offers opportunities for patients to participate in clinical trials for new treatments. Dr. David Woo, who has authored numerous peer-reviewed articles, regularly answers patients' questions about bladder cancer, kidney cancer, and other genitourinary cancers. With a focus on providing comprehensive and up-to-date information, IRAD Oncology INC. strives to support patients in their journey towards better health and offers a range of resources, including urology news feeds and informative articles on symptoms, treatment, prevention, and research..